{"DataElement":{"publicId":"2916271","version":"1","preferredName":"Prostate Carcinoma American Urological Association Symptom Score","preferredDefinition":"a number or range of numeric values measuring performance, function, quality, or ability for the American Urological Association Symptom Score related to prostate cancer.","longName":"PRS_AUA_SC","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2916268","version":"1","preferredName":"Prostate Carcinoma International Prognostic Index","preferredDefinition":"information related to international prognostic factors related to prostate cancer.","longName":"PRS_IPSS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2500203","version":"1","preferredName":"International Prognostic Index","preferredDefinition":"A list of five factors that help doctors assess how a non-Hodgkins lymphoma patient might respond to a certain treatment or predict the risk of disease recurrence and survival following therapy.  The factors are: 1) patient's age, 2) stage of disease: an indication of how localized or widespread is the disease, 3) LDH levels: serum levels often correlate with the amount of tumor in the body, 4) the number of extranodal, non-lymphatic sites found, 5) the patient's overall health. (from Lymphoma Research Foundation of America glossary (www.lymphoma.org))","longName":"C20118","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Prognostic Index","conceptCode":"C20118","definition":"A list of five factors that help doctors assess how a non-Hodgkin lymphoma patient might respond to a certain treatment or predict the risk of disease recurrence and survival following therapy.  The factors are: 1) patient's age, 2) stage of disease: an indication of how localized or widespread is the disease, 3) LDH levels: serum levels often correlate with the amount of tumor in the body, 4) the number of extranodal, non-lymphatic sites found, 5) the patient's overall health. (from Lymphoma Research Foundation of America glossary (www.lymphoma.org))","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"19915041-6A26-3CA4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-07-27","modifiedBy":"ONEDATA","dateModified":"2006-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E4A408F-36EB-9242-E040-BB89AD435AA9","latestVersionIndicator":"Yes","beginDate":"2009-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2916269","version":"1","preferredName":"American Urological Association Symptom Score","preferredDefinition":"a number or range of numeric values measuring performance, function, quality, or ability for the American Urological Association Symptom Score.","longName":"AUA_SCORE","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008575","version":"1","preferredName":"Symptoms","preferredDefinition":"signs that a person has a condition or disease. Some examples of symptoms are headache, fever, fatigue, nausea, vomiting, and pain(NCI). ","longName":"SM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB883C03-CF97-2540-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-04-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-04-17","modifiedBy":"MSUPLEY","dateModified":"2004-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2193207","version":"1","preferredName":"Score","preferredDefinition":"A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"EACFDBFA-EFD4-25E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-12-09","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E4A408F-36FD-9242-E040-BB89AD435AA9","latestVersionIndicator":"Yes","beginDate":"2009-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-09","modifiedBy":"ONEDATA","dateModified":"2009-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4171064","version":"1","longName":"RTOG-0815","context":"NRG"}]}],"AlternateNames":[{"name":"DCP","type":"USED_BY","context":"DCP"},{"name":"PRS_AUA_SC","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"AUA score","type":"Preferred Question Text","description":"AUA score","url":null,"context":"CTEP"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"6E4A408F-3711-9242-E040-BB89AD435AA9","latestVersionIndicator":"Yes","beginDate":"2009-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-09","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}